{"id":745014,"date":"2025-05-27T15:30:01","date_gmt":"2025-05-27T15:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=745014"},"modified":"2025-05-27T15:30:01","modified_gmt":"2025-05-27T15:30:01","slug":"synergy-chc-corp-nasdaq-snyr-eyes-roth-capitals-target-amid-profit-streak-global-expansion-sector-momentum","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/synergy-chc-corp-nasdaq-snyr-eyes-roth-capitals-target-amid-profit-streak-global-expansion-sector-momentum_745014.html","title":{"rendered":"Synergy CHC Corp. (NASDAQ: SNYR) Eyes Roth Capital\u2019s Target Amid Profit Streak, Global Expansion & Sector Momentum"},"content":{"rendered":"
\"Synergy<\/a><\/div>\n

Synergy CHC Corp. (NASDAQ: SNYR)<\/strong> is rapidly emerging as one of the most compelling small-cap opportunities in the booming consumer health sector. With shares trading around $1.96<\/strong>, Roth Capital<\/strong> has issued a Buy<\/strong> rating and a $10 price target<\/strong>, pointing to significant upside<\/strong> backed by strong fundamentals.<\/p>\n

In Q1 2025<\/strong>, Synergy posted GAAP EPS of $0.10<\/strong> on $8.2 million in revenue<\/strong>, marking its ninth consecutive quarter of profitability<\/strong>. Gross margins surged to 75.4%<\/strong>, up from 72.0% YoY, driven by an improved product mix. Looking ahead, analysts forecast $47.1 million in 2025 revenue<\/strong>, with EPS projected to climb as consumer health demand accelerates.<\/p>\n

The company’s flagship brands—FOCUSfactor<\/strong> and Flat Tummy<\/strong>—are gaining market share and fueling international expansion, including the launch of a Mexico subsidiary<\/strong> and a new Ready-To-Drink<\/strong> product line. Synergy is also proactively refinancing debt to extend maturity to 2029<\/strong>, strengthening its financial position for long-term growth.<\/p>\n

With a scale-ready product suite<\/strong>, global reach, and growing brand momentum, Synergy CHC is well-positioned to capitalize on a thriving market. Roth Capital report<\/a>.<\/p>\n

Synergy CHC Corp. (NASDAQ: SNYR)<\/strong> has been featured alongside industry innovators including Navitas Semiconductor (NASDAQ: NVTS), Vigil Neuroscience (NASDAQ: VIGL), Longevity Health Holdings (NASDAQ: XAGE), MicroAlgo Inc. (NASDAQ: MLGO), Peraso Inc. (NASDAQ: PRSO), NVIDIA (NASDAQ: NVDA),<\/strong> and Health In Tech Inc. (NASDAQ: HIT) see article<\/a> <\/strong>— spotlighting key players driving momentum across AI, biotech, and consumer health. SNYR also shares coverage with breakout disruptors SharpLink Gaming Inc. (NASDAQ: SBET), E2open Holdings (NYSE: ETWO),<\/strong> and MicroCloud Hologram Inc. (NASDAQ: HOLO)<\/strong> in our multi-sector review of high-potential stocks under $10. See the full article for complete insights.<\/a><\/strong><\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Synergy CHC Corp. (NASDAQ: SNYR) is rapidly emerging as one of the most compelling small-cap opportunities in the booming consumer health sector. With shares trading around $1.96, Roth Capital has issued a Buy rating and a $10 price target, pointing … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,426,402,405,431],"tags":[],"class_list":["post-745014","post","type-post","status-publish","format-standard","hentry","category-Business","category-Financial-Market","category-Food-Beverage","category-Health-Medicine","category-Sports"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/745014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=745014"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/745014\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=745014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=745014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=745014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}